biosafety.kz

Research institute for biological safety problems

Laboratory for Control of Technologies and Biopreparations

Head of the laboratory Kamshat Abitkhanovna Shorayeva, PhD. Specialist in the field of catalysis, organic, physical and biological chemistry. Author of more than 60 scientific papers, including 3 copyright certificates for inventions. The Hirsch index (h-index) in Web of Science and Scopus is 4.0. In 2020, she was awarded the “Алғыс хат – (Algys Khat – Appreciation letter)” medal of the Ministry of Education and Science of the Republic of Kazakhstan. For merits in the development and production of the COVID-19 coronavirus infection vaccine QazVac in 2021, she was awarded the medal “Халық алғысы (Halyk Algysy – People’s gratitude)”.

Main tasks:

  • Organization and conduct of technological and biological quality control of biological products for compliance with the requirements of GOST ISO/IEC 17025 “General requirements for the competence of testing and calibration laboratories” (accreditation certificate NoKZ.T.08.1389);
  • Development of regulatory documentation on the organization and conduct of quality control and safety of biological products;
  • Organization and conduct of registration tests of biological products;
  • Organization and conduct of preclinical and clinical study of medical immunobiological preparations.

Main achievements:

  • development technologies for the manufacture of rinderpest, equine influenza, Aujeski disease, avian influenza and foot-and-mouth disease type A and O inactivated vaccines;
  • development of scientifically based recommendations for anti-epizootic measures for such especially dangerous infections as rinderpest, avian influenza, foot-and-mouth disease, etc.;
  • rules for epizootological monitoring of especially dangerous and exotic diseases of animals and birds;
  • development of a strategy for combating avian influenza, principles for organizing and carrying out preventive and anti-epidemic measures in the foci of an outbreak of highly pathogenic avian influenza in the Republic of Kazakhstan;
  • development of recommendations aimed at reducing the socio-economic consequences of avian influenza;
  • development of “National requirements for methods of quality and safety control of inactivated influenza vaccine at enterprises of the biological industry of the Republic of Kazakhstan”;
  • methods of quality control of inactivated influenza vaccine for public health (ORID, ELISA, Lal-test);
  • preclinical and clinical trials of experimental series of inactivated influenza vaccine for public health (Kazfluvac® – influenza A/H5N1 inactivated vaccine and Refluvac® – influenza A/H1N1 inactivated vaccine);
  • preclinical and clinical trials of experimental series of seasonal influenza trivalent split vaccine for public health.

Main publications:

  1. Nurpeisova A.S., Kydyrbayev Zh.K., Tabynov K.K., Valdovska A., Kozhamkulov Y.M., Inkarbekov D.A., Mailybayeva A., Jekebekov K.K., Abitayev R.T., Assanzhanova N.N., Khairullin B.M. Optimizing conditions for culturing subtype Н7 influenza viruses to update the strain composition of a commercial inactivated emulgated vaccine // News of the national academy of sciences of the republic of Kazakhstan series of agricultural sciences ISSN 2224-526Х Volume 2, Number 56 (2020), 47-53 https://doi.org/10.32014/2020.2224-526X.12.
  2. Mamadalyiev S., Nurpeysov A.*,Khairullin B., Kasenov M.M., Bogdanov N., Kydyrbaev Zh., Abduraimov Y., Volgin E., Kondybayeva Zh., Issagulov T., Sarsenbayeva G., Kiselev O., Tsybalova L., Migunov A., Stukova M., Zaytseva M., Satybaldieva Zh., Shin S., Shnaukshta V. Preclinical Testing of Refluvac®, A Vaccine Against Pandemic Influenza A/H1N1V // Journal of Applied Environmental and Biological Sciences, V. 1(3), P. 48-53.
  3. Sarsenbayeva G.J., Khairullin B.M., Kasenov M.M., Sansyzbay A.R., Volgin Y.N., Nurpeisova A.S., Issagulov T.E., Bogdanov N.V. Comparative Study of Methods for Extraction of Highly Purified Hemagglutinin from H5N1 Influenza Virus Recombinant Strain (A/Astana/6:2/2009) // Journal of Applied Environmental and Biological Sciences. 3(11), P. 29-35.
  4. Sansyzbay A.R., Erofeeva M.K., Khairullin B.M., Kasenov M.M., Sandybayev N.T., Kydyrbayev Zh.K., Mamadaliyev S.M., Sergeeva M.V., Romanova J.R., Krivitskaya V.Z., Kiselev O.I., Stukova M.A. An Inactivated, Adjuvanted whole virion clade 2.2 H5N1 (A/chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in hu-mans // Clinical and Vaccine Immunology. Vol. 20, Number 8, P.1314-1319. https://doi:10.1128/CVI.00096-13.
  5. Sarsenbayeva G.J., Khairullin B.M., Kasenov M.M., Sansyzbay A.R, Volgin Y.N., Nurpeisova A.S., Issagulov T.E., Bogdanov N.V., Volgin Y.N., Issagulov T. E., Bogdanov N.V., Nurpeissova A.S., Kasenov M.M., Sagymbai A., Abitay R., Stukova M.A., Sansyzbay A.R., Khairullin B.M. Comparative Study of Methods for Extraction of Highly Purified Hemagglutinin from H5N1 Influenza Virus Recombinant Strain (A/Astana/6:2/2009) // Journal of Applied Environmental and Biological Sciences 3(11), P. 29-35.
  6. Sarsenbayeva G., Volgin Y., Issagulov T., Bogdanov N., Sansyzbay A., Kasenov M.M., Abitay R., Nurpeissova A., Sagymbay A., Kochemetov Zh., Stukova M., Buzitskaya Zh., Kulmaganbetov I., Karabaeva D., Davlyatshin T., Khairullin B. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized and placebo-controlled trial // Journal of Medical Virology. Volume 90. P.41-49. http://doi:10.1002/jmv.24922.
  7. Sarsenbayeva G., Volgin Y., Issagulov T., Bogdanov N., Kasenov M.M., Sansyzbay A., Kulmaganbetov I., Stukova M., Buzitskaya Zh., Davlyatshin T., Khairullin B. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults // Human Vaccines & Immunotherapeutics. Vol. 14, No.3. P. 609-614, http://dx.doi.org/10.1080/21645515.2017.1387345.
  8. Nurpeisova, A. Makbuz, A.Sansyzbay, A.Voldovska, B. Khairullin, Kasenov M. Assessment of the immunogenicity and protective effectiveness of Refluvac® in mice challenged with a pandemic A/H1N1 influenza // Research for rural development. Vol. 1. P. 271-276, http://doi:10.22616/rrd.24.2018.043.
  9. Nurpeisova A., Rametov N., Tabynov K., Volgin Ye., Sagymbay A., Makbuz A., Kasenov M., Sansyzbay A., Khairullin B. Analysis of Efficacy of Adjuvant-based Inactivated Pandemic H5N1 Influenza Virus Vaccine // Archives of Virology, International scientific journal, Springer Vienna. – Vol. 164(4), Р. 1027-1036. http://doi:10.1007/s00705-019-04147-7.
  10. Sarsenbayeva G., Issagulov T., Volgin Y., Abitay R., Bogdanov N., Sansyzbay A., Kasenov M., Pisareva M., Stukova M., Кulmagambetov I., Davlyatshin T., Nurpeisova A., Kutumbetov L., Khairullin B. Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan // Human Vaccines & Immunotherapeutics. P.1-7. http://doi:10.1080/21645515.2019.1705691.
  11. Mamadaliyev S., Sandybayev N., Kydyrbayev Zh., Khairullin B., Zaitsev V., Mambetaliyev M., Kassenov M., Chervyakova O., Ryskeldinova Sh., Volgin Y., Nurpeisova A., Bogdanov N., Sarsenbayeva G., Kiselev O., Tsybalova L., Grudinin M., Migunov A., Stukova M. Basic results of development of a production technology and control of a pandemic influenza A/H5N1 vaccine // Influenza and Other Respiratory Viruses. Vol. 5, S.1. P. 350-353. https://doi.org/10.1111/j.1750-2659.2011.00209.x
  12. Mamadaliyev S., Sandybayev N., Kydyrbayev Zh., Khairullin B., Zaitsev V., Mambetaliyev M., Kassenov M., Chervyakova O., Ryskeldinova Sh., Volgin Y., Nurpeisova A., Bogdanov N., Sarsenbayeva G., Kiselev O., Tsybalova L., Grudinin M., Migunov A., Stukova M. Development of production technology and pre-clinical testing of a pandemic influenza A/H1N1 vaccine // Influenza and Other Respiratory Viruses. Vol. 5, S.1. P. 354-357. https://doi.org/10.1111/j.1750-2659.2011.00209.x
  13. Khairullin B., Zakarya K., Orynbayev M., Abduraimov Y., Kassenov M., Sarsenbayeva G., Sultankulova K., Chervyakova O., Myrzakhmetova B., Nakhanov A., Nurpeisova A., Zhugunissov K., Assanzhanova N., Nurabayev S., Kerimbayev A., Yershebulov Z., Burashev Y., Kulmagambetov I., Davlyatshin T. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine 2022:50:101526.
  14. Nurpeisova A., Khairullin B., Abitaev R., Shorayeva K., Jekebekov K., Kalimolda E., Kerimbayev A., Akylbayeva K., Abay Zh., Myrzakhmetova B., Nakhanov A., Absatova Zh., Nurabayev S., Orynbayev M., Assanzhanova N., Abeuov K., Kutumbetov L., Kassenov M., Abduraimov Y., Zakarya K. Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19 // Human Vaccines and Immunotherapeutics. https://doi:10.1080/21645515.2022.2087412. 2022 г.

Services:

  1. Evaluation of the main biological, physicochemical and immunobiological parameters of viral vaccines and test systems for laboratory diagnostics.
  2. Conducting research to determine the harmlessness and immunogenicity of viral vaccines.
  3. Conducting preclinical and clinical trials of new biologics.